Toll Free: 1-888-928-9744

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 79 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H2 2016, provides an overview of the Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline landscape.

Cushing disease is a condition in which the pituitary gland releases too much adrenocorticotropic hormone (ACTH). Symptoms include acne or skin infections, backache, mental changes, such as depression, anxiety, or changes in behavior. Treatment includes surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 2, 5 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pituitary ACTH Hypersecretion (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Metabolic Disorders)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Pituitary ACTH Hypersecretion (Cushing Disease) Overview 8 Therapeutics Development 9 Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Overview 9 Pipeline Products for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis 10 Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Development by Companies 11 Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics under Investigation by Universities/Institutes 12 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Development by Companies 16 Pituitary ACTH Hypersecretion (Cushing Disease) - Products under Investigation by Universities/Institutes 17 Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development 18 Amryt Pharma plc 18 Corcept Therapeutics Inc 19 Cyclacel Pharmaceuticals Inc 20 ElexoPharm GmbH 21 Ipsen SA 22 Millendo Therapeutics Inc 23 Novartis AG 24 Orphagen Pharmaceuticals Inc 25 Pfizer Inc 26 Reset Therapeutics Inc 27 Strongbridge Biopharma plc 28 XOMA Corp 29 Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Target 31 Assessment by Mechanism of Action 34 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 AP-102 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 ATR-101 - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BIM-23B065 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ketoconazole - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 levoketoconazole - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 mifepristone - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Monoclonal Antibodies to Antagonize Adrenal Corticotropic Hormone Receptor for Cushing's Disease - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 MPP-482 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 osilodrostat phosphate - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 pasireotide ER - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 seliciclib - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease and Congenital Adrenal Hyperplasia - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 veldoreotide - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects 72 Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products 73 Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones 74 Featured News & Press Releases 74 Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder 74 Jan 29, 2015: COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society's 97th Annual Meeting & Expo 74 Oct 03, 2014: Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014 75 Sep 30, 2014: Cortendo AB to Present at the Epic Biotech Conference in London on October 2, 2014 75 Sep 29, 2014: Cortendo AB to Present at the 14th Annual BIOTECH in Europe Forum in Basel September 30, 2014 75 Aug 12, 2014: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting 75 Jul 09, 2014: CORTENDO Reports Continued Progress On Phase 3 SONICS Trial 76 Jul 30, 2012: Cortendo's NormoCort Receives Orphan Drug Designation From EMA To Treat Cushing's Syndrome 76 Mar 15, 2012: Cortendo Receives FDA Orphan Drug Designation For NormoCort In Cushing's Syndrome 77 Appendix 78 Methodology 78 Coverage 78 Secondary Research 78 Primary Research 78 Expert Panel Validation 78 Contact Us 78 Disclaimer 79
List of Tables
Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), H2 2016 9 Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease) - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 11 Number of Products under Investigation by Universities/Institutes, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Clinical Stage Development, H2 2016 14 Comparative Analysis by Early Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Amryt Pharma plc, H2 2016 18 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Corcept Therapeutics Inc, H2 2016 19 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 20 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by ElexoPharm GmbH, H2 2016 21 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Ipsen SA, H2 2016 22 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Millendo Therapeutics Inc, H2 2016 23 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Novartis AG, H2 2016 24 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Orphagen Pharmaceuticals Inc, H2 2016 25 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Pfizer Inc, H2 2016 26 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Reset Therapeutics Inc, H2 2016 27 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, H2 2016 28 Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by XOMA Corp, H2 2016 29 Assessment by Monotherapy Products, H2 2016 30 Number of Products by Stage and Target, H2 2016 32 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, H2 2016 72 Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, H2 2016 73



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify